EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Automated eye-tracking for Parkinson's disease diagnosis: a proof-of-concept cascade classifier study

J Michael Menke, Sana Aslam, Hector Rieiro, Ron Waldorf, Holly A Shill

Clinical Parkinsonism & Related Disorders · 2026 · 15 · 100509

DOI: 10.1016/j.prdoa.2026.100509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Parkinsonism & Related Disorders, 2026. Verfasst von J Michael Menke und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona, Tucson, AZ 85721, USA. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson's disease (PD) is a progressive neurodegenerative disorder of increasing prevalence, with diagnostic accuracy of approximately 26% in early symptomatic patients. There is a need for accurate, non-invasive biomarkers to aid in disease diagnosis.

Methods

This proof-of-concept study enrolled 90 participants (PD n = 30, other movement disorders [OM] n = 30, healthy controls [HC] n = 30) at a single institution. Participants completed two 10-min eye- tracking sessions using the SaccadeDX™ 250-Hz binocular system. A two-level cascade classifier was fitted using elastic-net feature selection followed by logistic regression on the selected features, validated by 10-fold cross-validation. The cascade distinguished HC from movement disorders (Level 1) and PD from OM (Level 2), with the objective of establishing clinical validity - that an eye-tracking signal correlates reliably with PD diagnosis.

Results

Level 1 achieved an area under the curve (AUC) of 0.818 (95% CI: 0.71, 0.91), with a sensitivity of 83% and specificity of 63%. Level 2 achieved an AUC of 0.670 (95% CI: 0.52, 0.80), with a sensitivity of 68% and specificity of 63%. As a proof-of-concept study, the observed performance positions the device as an adjunctive screening tool. Diagnostic discrimination can only be achieved through a much larger Phase III study. Five adverse events were recorded (three cases of dizziness, one of nausea, and one of dry eyes); one participant withdrew from the study.

Conclusions

Preliminary evidence supports clinical validity pending confirmatory Phase III study: reproducible eye-tracking signal for PD is detectable using a two-level cascade classifier. A multi-center confirmatory study is warranted before assessment of clinical utility.

Trial registration

ClinicalTrials.govNCT04925622.

Schlagwörter

Stichwörter der Autor:innen

Cascade classifierClinical validityCross-validationElastic netEye trackingParkinson's diseaseSaccades

Autor:innen und Institutionen

  • University of Arizona, Tucson, AZ 85721, USA.
  • Barrow Neurological Institute, 240 West Thomas Road, Suite 301, Phoenix, AZ 85013, USA.
  • Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, USA.
  • Consultant, Cleveland, OH, USA.

Zitieren

APA

Menke, J. M., Aslam, S., Rieiro, H., Waldorf, R., & Shill, H. A. (2026). Automated eye-tracking for Parkinson's disease diagnosis: a proof-of-concept cascade classifier study. Clinical Parkinsonism & Related Disorders, 15, 100509. https://doi.org/10.1016/j.prdoa.2026.100509

Vancouver

Menke JM, Aslam S, Rieiro H, Waldorf R, Shill HA. Automated eye-tracking for Parkinson's disease diagnosis: a proof-of-concept cascade classifier study. Clinical Parkinsonism & Related Disorders. 2026;15:100509. doi:10.1016/j.prdoa.2026.100509

BibTeX
@article{Menke2026,
  author = {Menke, J Michael and Aslam, Sana and Rieiro, Hector and Waldorf, Ron and Shill, Holly A},
  title = {Automated eye-tracking for Parkinson's disease diagnosis: a proof-of-concept cascade classifier study},
  journal = {Clinical Parkinsonism & Related Disorders},
  year = {2026},
  volume = {15},
  pages = {100509},
  doi = {10.1016/j.prdoa.2026.100509}
}
Kostenlos starten →